Status:
COMPLETED
Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer
Lead Sponsor:
European Lung Cancer Working Party
Conditions:
Non Small Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary aim of the study is to identify a predictive molecular signature for response to chemotherapy, according to WHO criteria, in patients with non-small cell lung cancer by studying the transc...
Eligibility Criteria
Inclusion
- Histological diagnosis of non-small-cell lung cancer (NSCLC)
- Obtention of a biopsy of the tumour according to the procedure defined in the protocol
- NSCLC of any stage to be treated by standard conventional first-line chemotherapy, as defined in the ELCWP guidelines (www.elcwp.org)
- Presence of at least one assessable lesion
- Availability for participating in the detailed follow-up of the protocol
- Signed informed consent.
- Age above 18 years
Exclusion
- Patient who was previously treated with chemotherapy for NSCLC or who has any contra-indication precluding the administration of conventional chemotherapy for NSCLC
- NSCLC treated by exclusive surgery or radiotherapy
- A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year disease free interval)
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00864266
Start Date
March 1 2009
End Date
June 1 2020
Last Update
June 26 2020
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pneumology Clinique Saint-Luc
Bouge, Belgium, 5004
2
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet
Brussels, Belgium, 1000
3
Service de Pneumologie Hôpital Erasme
Brussels, Belgium, 1070
4
Department of Pneumology Hôpital Saint-Joseph
Gilly, Belgium, 6060